流感病毒灭活疫苗研究进展  

Novel Development of Inactivated Influenza Vaccine Research

作　　者：吕进[1] 王希良（审校者）[2] 

机构地区：[1]军事医学科学院微生物流行病研究所、病原微生物生物安全国家重点实验室免疫室,北京100071 [2]军事医学科学院微生物流行病研究所、病原微生物生物安全国家重点实验室免疫室

出　　处：《国际免疫学杂志》2007年第2期125-128,F0003,共5页International Journal of Immunology

摘　　要：流感病毒灭活疫苗白1945年在美国首先获准上市以来，已广泛应用于临床。但由于其不能刺激机体产生分泌型免疫球蛋白A（sIgA）的粘膜免疫保护作用；制备过程严重依赖于鸡胚；接种途径单一；以及不同型别间交叉免疫保护效果较差等缺点，限制了其应用范围。我国白2005年7月1日起禁止肌肉注射免疫中使用铝盐佐剂，为流感病毒灭活疫苗的研究提出了新的课题——提高流感病毒灭活疫苗的安全性、有效性，以应对流感的暴发流行。Inactivated influenza vaccine has been used widely around the world since it was first licensed in USA in 1945. Its application has been limited for its shortcomings such as fail to elicit secretory IgA ,heavily egg-based ,intramuscular administration ,less effective to betero-subtypes etc. The prohibition of aluminum adjuvant in intramuscular administration since July 1,2005 in China makes inactivated influenza vaccine research face a new challenge. Novel strategies needs to be pursued to increase the immunogenicity of inactivated influenza vaccine ,thereby increasing the overall quantity and quality of available material. This article will briefly review these different strategies and outline some of the potential advantages and challenges associated with them. ds

关 键 词：流感病毒 灭活疫苗 粘膜佐剂 

分 类 号：R3[医药卫生—基础医学]